Skip to main content

Don’t Rely on Your Prescription

  • 99 Accesses

Abstract

Most likely it’s not working for you. When you are prescribed a medicine and take it, you do so in the hope that you will have a benefit from it. Why else would you take it? But, unfortunately, in far too many cases, that hope is deceptive. Because every day, millions of people take medications that won’t benefit them.

This is a preview of subscription content, access via your institution.

Buying options

eBook
USD   19.99
Price excludes VAT (USA)
  • ISBN: 978-3-030-95293-8
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   29.99
Price excludes VAT (USA)
Fig. 2.1
Fig. 2.2
Fig. 2.3

Notes

  1. 1.

    Mukherjee D & Topol EJ (2002) Pharmacogenomics in cardiovascular diseases. Prog Cardiovasc Dis 44:479–498, https://doi.org/10.1053/pcad.2002.123467

  2. 2.

    Currie GP et al. (2006) Long-acting beta2-agonists in asthma: not so SMART? Drug Saf 29:647–656, https://doi.org/10.2165/00002018-200629080-00002

  3. 3.

    The NNT. Therapy (NNT) Reviews https://www.thennt.com/home-nnt/

  4. 4.

    Cochrane Germany. Cochrane systematic reviews https://www.cochrane.de/de/systematische-uebersichtsarbeiten

  5. 5.

    Fernandez G et al. (2011) Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 78:393–403.

  6. 6.

    Jackevicius CA et al. (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002; 288:462–467.

  7. 7.

    Culver AL et al. (2012) Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med 172:144–52.

  8. 8.

    Wieseler et al. (2019) New drugs: where did we go wrong and what can we do better? BMJ 366:I4340.

  9. 9.

    Makady A et al. (2018) Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies. Pharmacoeconomics. 36:359–368, https://doi.org/10.1007/s40273-017-0596-z

  10. 10.

    Eichler HG et al. (2015) From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther 97:234–46, https://doi.org/10.1002/cpt.59 pmid:25669457.

  11. 11.

    Davis C et al. (2017) Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ 359:j4530, https://doi.org/10.1136/bmj.j4530 pmid:28978555.

  12. 12.

    Gyawali B et al. (2019) Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med, https://doi.org/10.1001/jamainternmed.2019.0462 pmid:31135808.

  13. 13.

    Pease AM et al. (2017) Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 357:j1680, https://doi.org/10.1136/bmj.j1680 pmid:28468750.

  14. 14.

    Woloshin S et al. (2017) The fate of FDA postapproval studies. N Engl J Med 377:1114–7, https://doi.org/10.1056/NEJMp1705800 pmid:28930510.

  15. 15.

    Tang J et al. (2018) Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol 29:84–91, https://doi.org/10.1093/annonc/mdx755 pmid:29228097.

  16. 16.

    Fojo T (2017) Cancer therapies and the problem of me too many. Semin Oncol 44:113, https://doi.org/10.1053/j.seminoncol.2017.06.004 pmid:28923208.

  17. 17.

    Weeks JC et al. (2012) Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367:1616–25, https://doi.org/10.1056/NEJMoa1204410 pmid:23094723; London AJ & Kimmelman J (2016) Accelerated drug approval and health inequality. JAMA Intern Med 176:883–4, https://doi.org/10.1001/jamainternmed.2016.2534 pmid:27295005.

    Wise PH (2016) Cancer drugs, survival, and ethics. BMJ 355:i5792, https://doi.org/10.1136/bmj.i5792 pmid:27920029.

  18. 18.

    Gordon N et al. (2018) Trajectories of Injectable Cancer Drug Costs After Launch in the United States. JCO 36:319–325.

  19. 19.

    Tang J et al. (2018) Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol 29:84–91.

  20. 20.

    Barmer GEK Drug Prescription Report 2013, www.khbrisch.de/files/barmer_gek_arzneimittelreport_2013.pdf

  21. 21.

    Van den Akker M et al. (1998) Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 51:367–75.

  22. 22.

    Budnitz DS et al. (2006) National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296:1858–66.

  23. 23.

    Schurig A et al. (2018) Adverse drug reactions (ADRs) in hospital emergency departments. Dtsch Arztebl Int 115:251–8, https://doi.org/10.3238/arztebl.2018.0251

  24. 24.

    Light D (2010) Bearing the risks of prescription drugs. In: Light DW, ed. The Risks of Prescription Drugs. New York, NY: Columbia University Press, pp. 1–39.

  25. 25.

    Wehling M (2011) Guideline-driven polypharmacy in elderly, multimorbid patients is basically flawed: there are almost no guidelines for these patients. J Am Geriatr Soc 59:376–77.

  26. 26.

    Chamber of Pharmacists of Lower Saxony. 2017. For more patient safety: Why do we need ward pharmacists? https://www.apothekerkammer-niedersachsen.de/index.php?did=26&view=3319,4&print=1

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Schmidt, H.H.H.W. (2022). Don’t Rely on Your Prescription. In: The end of medicine as we know it - and why your health has a future. Springer, Cham. https://doi.org/10.1007/978-3-030-95293-8_2

Download citation